Clinical Data Based on Phase I trial data currently available* OTX-TKI (Axitinib Intravitreal Implant) has been generally well tolerated and observed to have a favorablesafety profile, with no ocular serious adverse events to date in all cohorts [Cohort 1(200 µg), Cohort 2(400µg), Cohort 3a (600 µg) and Cohort 3b (400 µg + Anti-VEGF)] Preliminary biological signal of clinically-meaningful decrease in retinal fluid observed by 2 months inCohorts 2 (400 µg) & 3a (600 µg), and as early as a week in Cohort 3b (400 µg + Anti-VEGF) Therapy durability of 10 months observed in 400 µg Cohort 2 in some patients and one subject in 600 µgCohort 3a demonstrated durability of therapy for up to 6 months (follow-up ongoing)